Rahul Aggarwal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/958773/publications.pdf

Version: 2024-02-01

		236833	149623
66	3,572	25	56
papers	citations	h-index	g-index

67	67	67	5706
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical translation of hyperpolarized¹³C pyruvate and urea MRI for simultaneous metabolic and perfusion imaging. Magnetic Resonance in Medicine, 2022, 87, 138-149.	1.9	23
2	Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Immune Checkpoint Inhibitor Therapy in Prostate Cancer. European Urology, 2022, 81, 219-221.	0.9	17
3	In Vivo Profiling with ¹⁸F-YJH08 Reveals Diverse Tissue Patterns of Antagonist/Glucocorticoid Receptor Interactions. Molecular Pharmaceutics, 2022, 19, 704-709.	2.3	2
4	Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study. JCO Clinical Cancer Informatics, 2022, 6, e2100182.	1.0	0
5	A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Cancer Research Communications, 2022, 2, 570-576.	0.7	1
6	CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clinical Cancer Research, 2022, 28, 3066-3075.	3.2	10
7	Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2022, 28, 3979-3989.	3.2	8
8	Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 81-87.	2.0	14
9	Large remodeling of the Myc-induced cell surface proteome in B cells and prostate cells creates new opportunities for immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	8
10	Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models. Metabolites, 2021, 11, 139.	1.3	13
11	Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. Scientific Reports, 2021, 11, 5040.	1.6	40
12	Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing. JCO Precision Oncology, 2021, 5, 710-725.	1.5	6
13	Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. , 2021, 9, e002254.		21
14	Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2021, 5, 1200-1220.	1.5	17
15	Specialized computational methods for denoising, B 1 correction, and kinetic modeling in hyperpolarized 13 C MR EPSI studies of liver tumors. Magnetic Resonance in Medicine, 2021, 86, 2402-2411.	1.9	6
16	Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review. Translational Andrology and Urology, 2021, 10, 3130-3143.	0.6	9
17	A phase I/II study of rovalpituzumab tesirine in delta-like 3â€"expressing advanced solid tumors. Npj Precision Oncology, 2021, 5, 74.	2.3	27
18	A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 730.e9-730.e15.	0.8	2

#	Article	IF	Citations
19	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nature Communications, 2021, 12, 7349.	5.8	51
20	Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. JCO Oncology Practice, 2021, , OP2100480.	1.4	1
21	Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm. Molecular Imaging and Biology, 2020, 22, 208-216.	1.3	16
22	Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. Prostate Cancer and Prostatic Diseases, 2020, 23, 269-276.	2.0	68
23	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 83-93.	0.8	24
24	Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093608.	1.4	19
25	Accelerating precision medicine in metastatic prostate cancer. Nature Cancer, 2020, 1, 1041-1053.	5.7	45
26	Tipifarnib in recurrent, metastatic HRASâ€mutant salivary gland cancer. Cancer, 2020, 126, 3972-3981.	2.0	34
27	Coil combination methods for multi-channel hyperpolarized 13C imaging data from human studies. Journal of Magnetic Resonance, 2019, 301, 73-79.	1.2	27
28	Reply to A. Dalla Volta et al. Journal of Clinical Oncology, 2019, 37, 351-352.	0.8	0
29	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 76, 562-571.	0.9	104
30	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 531-538.	2.0	66
31	Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 910-916.	2.8	35
32	Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study. Clinical Genitourinary Cancer, 2019, 17, e92-e96.	0.9	19
33	Translation of Carbonâ€13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients. Magnetic Resonance in Medicine, 2019, 81, 2702-2709.	1.9	65
34	Defining the Prognostic and Predictive Impact of Germline DNA Repair Mutations in Patients with Metastatic Castration-resistant Prostate Cancer. European Urology, 2018, 73, 694-695.	0.9	0
35	Technique development of 3D dynamic CSâ€EPSI for hyperpolarized ¹³C pyruvate MR molecular imaging of human prostate cancer. Magnetic Resonance in Medicine, 2018, 80, 2062-2072.	1.9	47
36	A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. Oncologist, 2018, 23, 656-e64.	1.9	25

#	Article	IF	Citations
37	A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets. European Urology, 2018, 73, 306-307.	0.9	6
38	Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers. European Urology, 2018, 73, 845-846.	0.9	4
39	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. Journal of Clinical Oncology, 2018, 36, 2492-2503.	0.8	477
40	Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight, 2018, 3, .	2.3	43
41	Investigation of analysis methods for hyperpolarized 13Câ€pyruvate metabolic MRI in prostate cancer patients. NMR in Biomedicine, 2018, 31, e3997.	1.6	77
42	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	13.5	459
43	Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. European Urology Oncology, 2018, 1, 78-82.	2.6	74
44	A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naÃ¯ve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 149.e7-149.e13.	0.8	7
45	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repairâ€“deficient Prostate Cancer. European Urology, 2017, 72, 34-42.	0.9	179
46	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discovery, 2017, 7, 999-1005.	7.7	223
47	Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Molecular Cancer Research, 2017, 15, 1221-1229.	1.5	27
48	CTâ€“Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. Journal of Vascular and Interventional Radiology, 2017, 28, 1073-1081.e1.	0.2	30
49	Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer. Lancet Oncology, The, 2017, 18, 1436-1437.	5.1	1
50	Hyperpolarized 1-[13 C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer. European Urology, 2017, 72, 1028-1029.	0.9	127
51	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	288
52	⁶⁸Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. Journal of Nuclear Medicine, 2017, 58, 81-84.	2.8	166
53	Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Research, 2017, 19, 107.	2.2	19
54	Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. , 2017, 5, 75.		52

#	Article	IF	Citations
55	Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. Oncotarget, 2017, 8, 71447-71455.	0.8	23
56	Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundationâ€“Supported West Coast Prostate Cancer Dream Team. European Urology Focus, 2016, 2, 469-471.	1.6	12
57	A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer. Molecular Imaging and Biology, 2016, 18, 946-951.	1.3	33
58	Prednisone Use in Conjunction with Abiraterone Acetate: Is Patient Safety a Concern with Long-term Steroid Exposure?. European Urology, 2016, 70, 445-446.	0.9	0
59	Approaches to minimize castration in the treatment of advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 368-374.	0.8	6
60	The changing role of imaging in clinical care. Nature Reviews Urology, 2014, 11, 75-77.	1.9	3
61	Response to Subsequent Docetaxel in a Patient Cohort With Metastatic Castration-Resistant Prostate Cancer After Abiraterone Acetate Treatment. Clinical Genitourinary Cancer, 2014, 12, e167-e172.	0.9	32
62	Impact of patient ethnicity on the metabolic and immunologic effects of PI3Kâ€“mTOR pathway inhibition in patients with solid tumor malignancies. Cancer Chemotherapy and Pharmacology, 2014, 74, 359-365.	1.1	8
63	Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomes. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 719-726.	2.3	141
64	The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrateâ€resistant prostate cancer. Cancer, 2013, 119, 3636-3643.	2.0	17
65	Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment. Oncologist, 2011, 16, 264-275.	1.9	27
66	The Mechanism of Action of Estrogen in Castration-Resistant Prostate Cancer: Clues From Hormone Levels. Clinical Genitourinary Cancer, 2009, 7, E71-E76.	0.9	28